Keyphrases
Oncolytic Herpes Simplex Virus (oHSV)
100%
Malignant Glioma
100%
Oncolytic Virotherapy
100%
Recurrent GBM
62%
Human Subjects
50%
Tumor Microenvironment
25%
Principal Investigator
25%
GBM Tumor
25%
Clinical Trials
12%
Oncolytic Virus
12%
Unmet
12%
FDA-approved Drugs
12%
Microenvironment
12%
Unresolved Issues
12%
Immunostimulatory
12%
Bioinformatics
12%
Incurable Cancer
12%
Peripheral Blood
12%
Clinical Translation
12%
Intratumoral Administration
12%
Successful Completion
12%
Standard-of-care Therapy
12%
Myeloid Cells
12%
Phase 1 Trial
12%
Proteomic Signature
12%
Phase 1 Clinical Trial
12%
Herpes Simplex Virus Type 1 (HSV-1)
12%
Impact-based
12%
Lessons Learned
12%
Biostatistics
12%
Immunosuppression
12%
Potential Impact
12%
Immune Stimulation
12%
Medicine and Dentistry
Oncolytic Virotherapy
100%
Glioblastoma
100%
Human Subject
100%
Malignant Neoplasm
50%
Clinical Trial
50%
Tumor Microenvironment
50%
Intratumoral Drug Administration
25%
Biostatistics
25%
Immunosuppressive Drug
25%
Immunosuppressive Treatment
25%
Human Alphaherpesvirus 1
25%
Myeloid Cell
25%
Oncolytic Virus
25%
Cancer
25%
Proteomics
25%
Pharmacology, Toxicology and Pharmaceutical Science
Virotherapy
100%
Glioblastoma
100%
Homo sapiens
100%
Malignant Neoplasm
50%
Tumor Microenvironment
50%
Clinical Trial
50%
Immunosuppressive Agent
25%
Oncolytic Virus
25%
Human Alphaherpesvirus 1
25%
Biostatistics
25%